Grant: CIHR Clinician Scientist - Phase 2
McGill University
$300,000.00
BRUISE CONTROL: BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial.
FY 2009-10
Summary
Many patients requiring cardiac arrhythmia device surgery are on chronic blood thinners, usually Coumadin, to prevent stroke. The management of their blood thinners around the time of surgery presents a dilemma to physicians. Physicians usually treat these patients with a strategy known as "bridging anti-coagulation". In this strategy tablet blood thinners are discontinued for a few days before the surgery (it takes a few days for the effects of tablet blood thinners to be cleared) and the patient is bridged with injection blood thinners (Heparin). After surgery the patient is restarted on injection blood thinner for a few days while tablet blood thinner effect is building up to therapeutic levels. However there are a number of downsides to bridging anti-coagulation around device surgery. In particular there is a substantial risk of significant device pocket hematoma (large collection of blood around the device battery). Pocket hematoma in this situation is not always benign. Despite these risks the accepted standard of care in most centers is to bridge patients who are at moderate to high risk of stroke. Recently in response to these issues a number of centers have explored the option of performing device surgery without stopping tablet blood thinners. The early observational data from single centers would suggest a greatly reduced hematoma rate with this strategy. Despite these encouraging results most surgeons are reluctant to move to operating without stopping tablet blood thinners. Hence a direct head to head comparison of the two strategies at multiple centers with multiple surgeons is required. BRUISE CONTROL is a prospective, single blind, randomized, controlled trial. Patients will be randomly assigned to one of two treatment arms. In the conventional arm patents will be bridged. In the experimental arm patients will continue on tablet blood thinners. The primary outcome will be clinically significant hematoma.
Department
Program
CIHR Clinician Scientist - Phase 2
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
197181
Name
Essebag Vidal
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinician Scientist
Projecttitle
BRUISE CONTROL: BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial.
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
CIHR Clinician Scientist - Phase 2
Keyworddelim
Anticoagulation; Atrial Fibrillation; Defibrillator; Heparin; Pacemaker; Warfarin
Abstract
Many patients requiring cardiac arrhythmia device surgery are on chronic blood thinners, usually Coumadin, to prevent stroke. The management of their blood thinners around the time of surgery presents a dilemma to physicians. Physicians usually treat these patients with a strategy known as "bridging anti-coagulation". In this strategy tablet blood thinners are discontinued for a few days before the surgery (it takes a few days for the effects of tablet blood thinners to be cleared) and the patient is bridged with injection blood thinners (Heparin). After surgery the patient is restarted on injection blood thinner for a few days while tablet blood thinner effect is building up to therapeutic levels. However there are a number of downsides to bridging anti-coagulation around device surgery. In particular there is a substantial risk of significant device pocket hematoma (large collection of blood around the device battery). Pocket hematoma in this situation is not always benign. Despite these risks the accepted standard of care in most centers is to bridge patients who are at moderate to high risk of stroke. Recently in response to these issues a number of centers have explored the option of performing device surgery without stopping tablet blood thinners. The early observational data from single centers would suggest a greatly reduced hematoma rate with this strategy. Despite these encouraging results most surgeons are reluctant to move to operating without stopping tablet blood thinners. Hence a direct head to head comparison of the two strategies at multiple centers with multiple surgeons is required. BRUISE CONTROL is a prospective, single blind, randomized, controlled trial. Patients will be randomly assigned to one of two treatment arms. In the conventional arm patents will be bridged. In the experimental arm patients will continue on tablet blood thinners. The primary outcome will be clinically significant hematoma.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Essebag, Vidal
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~